Abstract
Introduction. Thanks to advances in modern medicine, it has been possible to significantly increase life expectancy. With the high effectiveness of methods for diagnosing and treating many chronic pathologies, a sharp increase in the number of elderly patients is expected. This cohort of patients has features including polymorbidity; polypharmacy, and low compliance. Taking direct oral anticoagulants (DOACs) is associated with a risk of hemorrhagic complications, which can be difficult to predict in elderly patients, especially those with impaired renal function.
Objective. To evaluate factors that increase the risk of taking direct oral anticoagulants in elderly patients with polypharmacy and chronic kidney disease based on the analysis of molecular and genetic markers.
Material and methods. For this study, a database was collected that included 503 patients observed at the Moscow State Budgetary Healthcare Institution “Hospital for War Veterans No.2 of the Moscow City Healthcare Department” for the period from April to September 2023 with atrial fibrillation and stage 2C–4C kidney disease. The questionnaire method was used, as well as the collection of clinical and laboratory data to evaluate DOAC-dependent complications – cases of bleeding, duration of DOAC administration. Additionally, molecular markers of endothelial dysfunction and inflammation were determined, as well as genetic polymorphisms associated with DOAC metabolism in kidney tissues.
Results. DOAC administration increases bleeding risks with a significant decrease in creatinine clearance (less than 45 ml/min/1.73m2), especially with dabigatran. This observation regarding dabigatran applied to patients in CKD stages C2 and C3a; with creatinine clearance less than 45 ml/min/1.73 m2, this drug was rarely used. The use of apixaban and rivaroxaban does not have a statistically significant increase in the incidence of hemorrhagic complications as renal failure progresses. A correlation was found between the level of molecular markers of endothelial dysfunction (eNOS, VEGF) and the risk of developing DOAC-dependent bleeding. Patients with the rs2032582 single nucleotide polymorphism of the ABCB1 (MDR1) gene had an increased risk of hemorrhagic complications when taking dabigatran.
Conclusion. The study of drug interactions and the association of DOAC intake with various endpoints in larger samples will help identify molecular and genetic predictors of adverse outcomes and adjust therapy. A personalized approach to DOAC prescription based on the assessment of kidney function, molecular markers of endothelial dysfunction, and the patient's genetic profile can significantly reduce the risk of hemorrhagic complications in geriatric patients.
Keywords
Authors and affiliations
A.P. Kondrahin(1, 2), E.G. Silina(3), M.S. Chernyaeva(2, 4), M.L. Maksimov(1, 5, 6), A.S. Belokopytov(1),
A.N. Babichev(1), Yu.E. Smirnova(1), S.A. Martynova(1), K.O. Shnaider(1, 6)
1-Federal State Autonomous Educational Institution of Higher Education “Russian National Research Medical University
named after N.I. Pirogov” of the Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, 117997,
Russian Federation; 2-Moscow State Budgetary Healthcare Institution “Hospital for War Veterans No.2 of the Moscow City Healthcare Department”, Volgogradskiy Prospekt, 168, Moscow, 109472, Russian Federation; 3-Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of The Ministry of Health of the Russian Federation, Dolgorukovskaya st., 4, Moscow, 127006, Russian Federation; 4Federal State Budgetary Institution of Continuing Professional Education “Central State
Medical Academy” of the Administrative Department of the President of the Russian Federation, Marshal Timoshenko St., 19,
build. 1A, Moscow, 121359, Russian Federation; 5-Kazan State Medical Academy – branch of the Russian Medical
Academy of Continuous Professional Education of the Ministry of Health of Russia, Butlerova st., 49, Kazan, Republic
of Tatarstan, 420012, Russian Federation; 6-Federal State Budgetary Educational Institution of Additional
Professional Education “Russian Medical Academy of Continuous Professional Education”, Ministry
of Health of Russia, Barrikadnaya st., 2/1, Moscow, 123995, Russian Federation
References
Максимов М.Л., Бонцевич Р.А., Бурашникова И.С. и др. Клиническая фармакология и рациональная фармакотерапия для практикующих врачей: учебник. Под ред. проф. М.Л. Максимова. Казань: ИД «МеДДоК», 2021; 948. [Maksimov M.L., Bontsevich R.A., Burashnikova I.S. and others. Clinical pharmacology and rational pharmacotherapy for practicing physicians: textbook. Edited by prof. M.L. Maksimov. Kazan: Publishing house "Meddock", 2021; 948 (in Russian).]
Gallagher P., Ryan C., Byrne S. et al. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008; 46 (2): 72–83. DOI: 10.5414/CPP46072.
Machado-Duque M.E., Castaño-Montoya J.P., MedinaMorales D.A., et al. Drugs with Anticholinergic Potential and Risk of Falls with Hip Fracture in the Elderly Patients: A Case-Control Study. J. Geriatr Psychiatry Neurol. 2018; 31 (2): 63–9. DOI: https://doi.org/10.1016/j.rcp.2020.11.004
Кузьмин О.Б. Хроническая болезнь почек: механизмы развития и прогрессирования гипоксического гломерулосклероза и тубулоинтерстициального фиброза. Нефрология. 2015; 19 (4): 6–16. [Kuzmin O.B. Chronic kidney disease: mechanisms of hypoxic glomerulosclerosis and tubulointerstitial fibrosis development and progression. Nephrology (Saint-Petersburg). 2015; 19 (4): 6–16 (In Russ.)]
Hanlon J.T., Handler S.M., Maher R.L., Schmader K.E. Geriatric Pharmacotherapy and Polypharmacy. In: Fillit H.M., Rockwood K., Young J.B. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. 8th ed. Elsevier 2017; 849–54.
Leelakanok N., Holcombe A.L, Lund B.C., et al. Association between polypharmacy and death: A systematic review and meta-analysis. J. Am. Pharm Assoc. 2017; 57 (6): 729–38. DOI: https://doi.org/10.1016/j.japh.2017.06.002
Baruth J.M., Gentry M.T., Rummans T.A. et al. Multidisciplinary Guideline for Polypharmacy in older people. Hosp Pract (1995). 2020; 48 (sup1): 56–62. DOI: https://doi.org/10.1080/21548331.2019.1706995
Смирнов А.В., Волков М.М. Роль витамина D в замедлении прогрессирования хронической болезни почек. Нефрология. 2008; 12 (4): 7–13. [Smirnov A.V., Volkov M.M. Role of vitamin D in slowing the progression of chronic kidney disease. Nephrology. 2008; 12 (4): 7–13 (In Russ.)]
Лисянская О.Ю. Гипоксия – ведущий фактор прогрессирования хронической болезни почек. Нефрология. 2016; 20 (1): 9–15. [Lisyanskaya O.Yu. Hypoxia – the leading factor in the progression of chronic kidney disease. Nephrology. 2016; 20 (1): 9–15 (In Russ.)]
Paré G., Eriksson N., Lehr T., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013; 127 (13): 1404–12. DOI: 10.1161/CIRCULATIONAHA.112.001233
Тайц Б.М. «10П медицина» в решении вопросов снижения смертности, увеличения продолжительности и повышения качества жизни пожилого населения. Клиническая геронтология. 2021; 27 (11–12): 76–9. [Tayts BM. «P10 Medicine» for lower mortality, longer life expectancy and better quality of life in elderly people. Clin Gerontol. 2021; 27 (11–12): 76–9 (in Russian)]